Compare MTR & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MTR | MBIO |
|---|---|---|
| Founded | 1979 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4M | 4.1M |
| IPO Year | N/A | 2023 |
| Metric | MTR | MBIO |
|---|---|---|
| Price | $2.04 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.4K | ★ 39.8K |
| Earning Date | 11-13-2026 | 11-06-2026 |
| Dividend Yield | ★ 11.30% | N/A |
| EPS Growth | N/A | ★ 98.99 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $405.45 |
| P/E Ratio | $22.60 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.02 | $0.37 |
| 52 Week High | $5.83 | $1.69 |
| Indicator | MTR | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 28.74 | 30.11 |
| Support Level | N/A | N/A |
| Resistance Level | $2.65 | $0.56 |
| Average True Range (ATR) | 0.15 | 0.03 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 4.15 | 14.81 |
Mesa Royalty Trust holds net overriding royalty interests in various oil and gas properties located in the: Hugoton field of Kansas, San Juan Basin field of New Mexico, and San Juan Basin Field of Colorado.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.